Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC)
Commercial Sponsor
Merck
Summary
Eligible patients will be randomised to receive pembrolizumab or a pembrolizumab-placebo, plus the investigators choice of one of three chemotherapy regimens and radiotherapy.